Evidence map›Paper›PMID 34355118›Full record

ArticleNanoscale advances2021

Identification of amyloid beta in small extracellular vesicles

Meruyert Imanbekova, Sorina Suarasan, Tatu Rojalin, Rachel R Mizenko, Silvia Hilt, Meghna Mathur, Paula Lepine, Michael Nicouleau, Nguyen-Vi Mohamed, Thomas M Durcan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  9. Review
  10. Influence of TiOMaterials (Basel, Switzerland) · 2022
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Meruyert ImanbekovaDepartment of Bioengineering, McGill University Montreal QC H3A 0E9 Canada sebastian.wachsmannhogiu@mcgill.ca.
Sorina SuarasanDepartment of Bioengineering, McGill University Montreal QC H3A 0E9 Canada sebastian.wachsmannhogiu@mcgill.ca.ORCID https://orcid.org/0000-0002-3387-480X
Tatu RojalinDepartment of Biomedical Engineering, University of California Davis CA 95616 USA.
Rachel R MizenkoDepartment of Biomedical Engineering, University of California Davis CA 95616 USA.
Silvia HiltDepartment of Biochemistry & Molecular Medicine, University of California Davis CA 95616 USA.
Meghna MathurThe Early Drug Discovery Unit (EDDU), Montreal Neurological Institute and Hospital, McGill University Montreal QC H3A 2B4 Canada.
Paula LepineThe Early Drug Discovery Unit (EDDU), Montreal Neurological Institute and Hospital, McGill University Montreal QC H3A 2B4 Canada.
Michael NicouleauThe Early Drug Discovery Unit (EDDU), Montreal Neurological Institute and Hospital, McGill University Montreal QC H3A 2B4 Canada.
Nguyen-Vi MohamedThe Early Drug Discovery Unit (EDDU), Montreal Neurological Institute and Hospital, McGill University Montreal QC H3A 2B4 Canada.
Thomas M DurcanThe Early Drug Discovery Unit (EDDU), Montreal Neurological Institute and Hospital, McGill University Montreal QC H3A 2B4 Canada.
Randy P CarneyDepartment of Biomedical Engineering, University of California Davis CA 95616 USA.ORCID https://orcid.org/0000-0001-8193-1664
John C VossDepartment of Biochemistry & Molecular Medicine, University of California Davis CA 95616 USA.ORCID https://orcid.org/0000-0001-9279-209X
Sebastian Wachsmann-HogiuDepartment of Bioengineering, McGill University Montreal QC H3A 0E9 Canada sebastian.wachsmannhogiu@mcgill.ca.ORCID https://orcid.org/0000-0002-3761-3834
Montreal Neurological Institute and Hospital · CAUniversity of California System · USMcGill University · CA

Funding

SERS diagnostics platform for liquid bioapsy analysis of tumor-associated exosomesR01CA241666 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARNEY, RANDY · 2020 to 2024
$2.5M
NCI NIH HHS R01 CA241666
6 · The paper itself

Abstract

One of the hallmarks of Alzheimer's disease (AD) pathogenesis is believed to be the production and deposition of amyloid-beta (Aβ) peptide into extracellular plaques. Existing research indicates that extracellular vesicles (EVs) can carry Aβ associated with AD. However, characterization of the EVs-associated Aβ and its conformational variants has yet to be realized. Raman spectroscopy is a label-free and non-destructive method that is able to assess the biochemical composition of EVs. This study reports for the first time the Raman spectroscopic fingerprint of the Aβ present in the molecular cargo of small extracellular vesicles (sEVs). Raman spectra were measured from sEVs isolated from Alzheimer's disease cell culture model, where secretion of Aβ is regulated by tetracycline promoter, and from midbrain organoids. The averaged spectra of each sEV group showed considerable variation as a reflection of the biochemical content of sEVs. Spectral analysis identified more intense Raman peaks at 1650 cm

Identifiers

PMID34355118
PMCPMC8276787
OpenAlexW3168415845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.